title: Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population.
abstract: OBJECTIVE
  To evaluate the frequency and epidemiological features of vernal keratoconjunctivitis (VKC) in Italy.
  
  
  METHODS
  a specific electronic clinical chart for vernal keratoconjunctivitis was created to standardize: 1) medical history; 2) diagnostic criteria; 3) signs and symptoms; and 4) treatments. This study involved 6 Italian referral centers for ocular surface diseases: between March 2005 and March 2006, all referred patients were included, clinical data collected and statistically examined.
  
  
  RESULTS
  The mean age of the vernal keratoconjunctivitis population (n = 156) was 13.8 +/- 8.8 with 64.1% of subjects under 14 years of age and a male/female ratio of 3.5:1. Among VKC patients, 48.7% showed associated systemic allergic diseases. Only 32.1% of patients were positive for RAST and/or prick test. The limbal form (53.8%) was the most frequent subtype of vernal keratoconjunctivitis. Approximately 9% of patients showed a severe form of vernal keratoconjunctivitis. At the first visit patients were treated with: multiple action or mast cell stabilizer eye drops (58.1% and 41.3% of cases, respectively), topical corticosteroids alone (0.6%) or in association (26.8% of cases). All patients used topical steroids at least once in the studied year. Systemic antihistamine therapy was used by 25.6% of patients. In this cohort, 32.7% of patients required two or more examinations per year for exacerbations of their symptoms.
  
  
  CONCLUSIONS
  Vernal keratoconjunctivitis is a severe ocular condition that mainly affects young males. Vernal keratoconjunctivitis is characterized by different clinical features and therapeutic responses, suggesting the need for a standardized therapeutic approach on the basis of a grading of disease severity.
authors.affiliation: Department of Ophthalmology, University Campus Bio-Medico, Rome, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lambiase
authors.forename: Simona
authors.initials: S
authors.lastname: Minchiotti
authors.forename: Andrea
authors.initials: A
authors.lastname: Leonardi
authors.forename: A G
authors.initials: AG
authors.lastname: Secchi
authors.forename: Maurizio
authors.initials: M
authors.lastname: Rolando
authors.forename: Giovanni
authors.initials: G
authors.lastname: Calabria
authors.forename: Jelka
authors.initials: J
authors.lastname: Orsoni
authors.forename: Enrica
authors.initials: E
authors.lastname: Zola
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ferreri
authors.forename: Pasquale
authors.initials: P
authors.lastname: Aragona
authors.forename: Alfredo
authors.initials: A
authors.lastname: Reibaldi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Chisari
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonini
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D017678:Sex Distribution
chemical_list: D005938:Glucocorticoids; D006633:Histamine Antagonists